Excellagen
Commercial- Indications
- Wound healing, Diabetic ulcers
Company intelligence / Profile preview
Cardium Therapeutics was a San Diego-based health sciences company focused on regenerative medicine and innovative therapies addressing cardiovascular diseases and wound care. Its lead product candidates included Generx®, a DNA-based gene therapy for myocardial ischemia that advanced through late-stage clinical trials, and Excellagen™, an FDA-cleared topical gel for chronic wounds. The company also developed the InnerCool Therapies endovascular cooling system before selling this business to Philips in July 2009. In March 2014, following a strategic collaboration with Shanxi Taxus Pharmaceuticals Co., Ltd., the company changed its name to Taxus Cardium Pharmaceuticals Group Inc.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Cardium Therapeutics, Inc..